Navigation Links
Alexza Reports 2010 Fourth Quarter and Full Year Financial Results and Provides General Corporate Update
Date:3/15/2011

novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.  Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company completed an end-of-review meeting with the FDA in late December 2010.  

The Company believes it has a clear understanding of the issues outlined in the CRL, is developing and executing a plan to address these issues, and currently projects a resubmission of the AZ-004 NDA in July 2011.  

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

Alexza's policy is to only provide guidance on product candidates and corporate goals for the future one to two fiscal quarters, and to provide, update or reconfirm its guid
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza to Announce 2010 Year-End Financial Results on Tuesday, March 15, 2011
2. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
3. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
4. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
5. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
6. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
7. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
8. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
9. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
10. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
11. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Texas , Aug. 21, 2014  eRelevance ... services company, announced today that it has completed ... (EMR) solution for Plastic Surgery and Dermatology practices. ... even more value to healthcare practices using Nextech," ... of eRelevance Corporation. "Using information from the EMR ...
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
(Date:8/21/2014)... Sasha is a 10 year old Alaskan malamute, ... little older, and is having trouble getting up and down, ... have an owner who purchased a Butler Mobility Inclined Platform ... could no longer get up and down the stairs from ... She had tried a stair lift, but had to transfer ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The Onder ... and product liability law, announces the launch of a ... comprehensive information on morcellator surgery lawsuits for ... FDA morcellator cancer warning and the July 2014 morcellator ... the April 17, 2014 FDA warning on morcellator surgery ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... NJ. August 21, 2014. Researchers have published a ... outcomes of patients with motor complete spinal cord ... in functioning at discharge and follow-up among patients ... of print on August 2 by the ... 10.1016/j.apmr.2014.07.398). Findings included small but significant differences in ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
Breaking Medicine News(10 mins):Health News:Sasha Gets a Butler Mobility Inclined Platform Lift 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2Health News:CHEST releases new expert guidance in care of the critically ill and injured 2
... often been associated with serious side-effects. Researchers at the ... mice, found a way of utilising the positive effects ... is acted on, current research at the Academy shows. ... PNAS (Proceedings of the National Academy of Sciences). ...
... bacterial DNA that often carries antibiotic resistance is a master ... widely differing bacterial species, shows a study made by ... with Chalmers University of Technology. The results are published in ... More and more bacteria are becoming resistant to our ...
... , MONDAY, April 11 (HealthDay News) -- Young mothers ... have children, and they also consume more saturated fat, ... Examining data from Project EAT (Eating and Activity ... of Minnesota focused on the link between parental status, ...
... Normal daily fluctuations in blood pressure aren,t linked with the ... heart attack or stroke in the morning, a new study ... who underwent three types of sleep/wake cycle experiments designed to ... daily rise and fall in blood pressure. In all ...
... pain can significantly reduce disability in older adults, according to ... newsletter from The Gerontological Society of America ... Annual Scientific Meeting in November 2010, the current WHAT,S HOT ... managing pain and preserving function, and methods to improve the ...
... , SUNDAY, April 10 (HealthDay News) -- Obese patients taking ... lost an average of 22 pounds over a year, while ... study has found. Qnexa is a combination of ... the United States, currently available under a variety of brand ...
Cached Medicine News:Health News:Antibiotic resistance spreads rapidly between bacteria 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 2Health News:Having Kids Might Make Young Women Heavier, Less Fit 3Health News:Effective pain management crucial to older adults' well-being 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 2Health News:Experimental Weight-Loss Drug Seems to Work: Study 3Health News:Experimental Weight-Loss Drug Seems to Work: Study 4
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... White to buff-colored powder Activity: >=590g of gentamicin/mg (dry ... tests Limit of Methanol: Specific Rotation (25C): +107 ... H 2 O): 3.5 to 5.5 Loss on drying: ... : 25-50% C 2 + C 2a : ...
... Gentamycin sulfate is effective against gram ... as mycoplasma, by interfering with bacterial protein ... of ribosomes. Its suggested working concentration of ... and mammalian cells, thereby making a gentler ...
Medicine Products: